SPOTLIGHT: New CEO to run GSK from London

When Andrew Witty (photo) takes over as CEO in May, he'll be running GlaxoSmithKline from London rather than from the U.S. HQ in Philadelphia as his predecessor Jean-Pierre Garnier did. No significant staff or resources will be relocated, and the company will continue to have a "dual headquarters" in both cities. Witty has been living in the UK as chief of the company's European operations. Report

Suggested Articles

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Intent-driven audiences are inspired to make health-improving changes after a positive online experience. Find out what they’re driven to do.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.